

## Another disappointing result for Tecentriq in triple negative breast cancer



Amy Brown

Anti-PD(L)-1 antibodies have a mixed record in triple negative breast cancer, and the failure of Impassion-131, a first-line trial of Roche's Tecentriq, is another black mark. Tecentriq failed to improve PFS versus paclitaxel in PD-L1-positive patients, [Roche said](#), while a negative trend on overall survival, a secondary endpoint, was detected. The trial was not sufficiently powered to show a benefit here and the data are still immature, but the study had already been upsized and the readout delayed, suggesting that the company was struggling to tease out even a marginal benefit. [Tecentriq has accelerated approval](#) in the US as a first-line treatment of TNBC in patients with least 1% PD-L1 expression, based on the Impassion-130 trial. This was similar in design to Impassion-131, but recruited more patients and used Abraxane instead of paclitaxel as the chemo comparator. There is some [suggestion that paclitaxel could have made a difference](#): the high dose steroid premedication required to stave off side effects has been associated with [diminished efficacy of immunotherapies](#). [Tecentriq's success in a neoadjuvant TNBC](#) study earlier this year arguably makes the Impassion131 failure less important, but it is clear that there is still much to be learned about the drug's role in this disease.

### Roche trials in triple-negative breast cancer

Study	Design	Primary endpoint(s)	Result
<i>Neoadjuvant</i>			
<a href="#">Impassion-031</a>	Tecentriq + Abraxane vs Abraxane	pCR in PD-L1+ and all-comers	Toplined positive in PD-L1+ and all-comers
<i>Neoadjuvant + adjuvant</i>			
<a href="#">NeoTRIPaPDL1</a>	Tecentriq + Abraxane vs Abraxane	EFS	Failed in Dec 2019
<a href="#">MO39875</a>	Tecentriq + chemo vs chemo	pCR & EFS	Dec 2023 primary completion
<i>Adjuvant</i>			
<a href="#">Impassion-030</a>	Tecentriq + chemo vs chemo	iDFS	Jan 2022 primary completion
<i>First-line</i>			
<a href="#">Impassion-130</a>	Tecentriq + Abraxane vs Abraxane	OS & PFS in PD-L1+ and all-comers	Approved in ≥1% PD-L1
<a href="#">Impassion-131</a>	Tecentriq + paclitaxel vs paclitaxel	PFS in PD-L1+ and all-comers	Failed in Aug 2020
<a href="#">Impassion-132</a>	Tecentriq + chemo vs chemo	OS in PD-L1+ and all-comers	Upsized by 63%, completion delayed from Jul 2019 to Jan 2023
<a href="#">Ipatunity-130</a>	Ipatasertib + chemo vs chemo	PFS in PIK3CA/AKT1/PTEN-altered	Dec 2021 primary completion

Source: [clinicaltrials.gov](https://clinicaltrials.gov) & company presentation.

